InsidersTradesSigma
AMPLIFON SPA Stock: price and directors' dealings · Italy · Consob
Follow the AMPLIFON SPA share price and the full insider trade history of the company, a publicly traded company based in Italy. Shares are listed on IT IT, under the oversight of Consob. Operating in the Healthcare & Pharma sector, AMPLIFON SPA has recorded 32 public disclosures. Market capitalisation: €2.8bn. The latest transaction was disclosed on 29 May 2026 (Grant). Among the most active insiders: ALBERTO FEDERICO ALDO BARDELLI. Every trade is accessible without an account.
32
Insider Decl.
0
Thresholds
€69,326
3 ops.
Buy Volume
€54,433
1 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate AMPLIFON SPA Hold (neutral), based on 16 analysts. Average price target: €12.97.
18Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 9,962 of 25,899 companies
57.8
score / 100
Value67
Quality49
FCF yld11%
Earn yld3.3%
EV/EBITDA9.0x
ROE6.2%
Gross mgn53%
Net mgn3.8%
Debt/EBITDA3.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 May 2026
Declarations32 total
2,045 shares0ShareCONSOB:185217
576 shares0ShareCONSOB:185216
1,091 shares0ShareCONSOB:185211
2,640 shares0ShareCONSOB:185212
2,136 shares0ShareCONSOB:185203
3,148 shares0ShareCONSOB:185199
1,019 shares0ShareCONSOB:185200
●
Persona che esercita funzioni di amministrazioneExecutives
5,000 shares@ €10.880.0020% mcap50.0% of flowShareXMILCONSOB:185201
Ideal exit: 21 Feb 2027 (T+270)
●
Persona che esercita funzioni di amministrazioneExecutives
5,000 shares@ €10.88660.0020% mcap50.0% of flowShareXMILCONSOB:185202
11,035 shares0ShareCONSOB:185204
1,443 shares0ShareCONSOB:185205
2,438 shares0ShareCONSOB:185206
2,500 shares0ShareCONSOB:185207
35,458 shares0ShareCONSOB:185208
2,274 shares0ShareCONSOB:185209
818 shares0ShareCONSOB:185210
7,955 shares0ShareCONSOB:185187
576 shares0ShareCONSOB:185188
4,285 shares0ShareCONSOB:185189
909 shares0ShareCONSOB:185190
3,909 shares0ShareCONSOB:185191
426 shares0ShareCONSOB:185195
21,433 shares0ShareCONSOB:185186
7,046 shares0ShareCONSOB:185192
2,640 shares0ShareCONSOB:185193
25 of 32 declarations
About AMPLIFON SPA
Amplifon S.p.A. is a global leader in retail hearing care, listed on Borsa Italiana (FTSE MIB) in Italy. The company was founded in Milan in 1950 by Algernon Charles Holland, originally with a social mission in the post-war period: to provide hearing solutions to people affected by war-related sound damage. Over time, Amplifon evolved from a local specialist into an international hearing-care platform focused on the assessment, fitting, distribution and long-term support of hearing aids and related services. Its global headquarters are in Milan, which also serves as the center for strategy, innovation and corporate governance. Amplifon’s business model is built around a dense retail network of hearing-care centers, operated both directly and through franchising in some markets, combined with a highly personalized customer journey. The group offers hearing aids, accessories, audiological testing, tailor-made fitting services, aftercare, and digital tools that support patient engagement and follow-up. This product-and-service mix is central to Amplifon’s competitive positioning, because hearing care is a trust-based category where clinical expertise, local presence, service quality and retention matter as much as the device itself. The company describes itself as the world leader in retail hearing care, with a global market share of around 13% in its corporate communications. It operates in 25 countries, with nearly 10,000 hearing-care centers and more than 20,000 employees, giving it a broad footprint across Europe, North America, Australia and parts of Latin America. This geographic diversification reduces reliance on any single national market and supports a more resilient long-term growth profile. Strategically, Amplifon emphasizes innovation, customer experience and digitalization, including proprietary tools and omnichannel services designed to improve access, diagnostics and ongoing care. Recent milestones include 2025 consolidated revenues of about €2.4 billion and the launch of the Fit4Growth plan, which aims to strengthen profitability and competitiveness through 2027. In early 2026, the company reported faster organic growth, a record adjusted EBITDA margin for the quarter, and further investments in audiological research and innovation. For investors, Amplifon remains a structurally attractive healthcare-related franchise benefiting from demographic trends, aging populations and the increasing prevalence of hearing-loss awareness, while operating from Italy within the FTSE MIB universe.
